
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc anticipates a rebound in enterprise sales, particularly from integrated delivery networks (IDNs), contingent on improvements in the macroeconomic environment. The company is making notable progress in enhancing its claims pipeline, which positions the Indego Personal exoskeleton to potentially become a significant revenue contributor in 2025 and subsequent years. Furthermore, Ekso Bionics is actively leveraging strategic partnerships to foster growth in the Indego Personal segment, indicating a proactive approach to expanding its market presence.
Bears say
Ekso Bionics Holdings Inc. reported a total revenue of $3.4 million in 1Q25, reflecting a 10% year-over-year decline from $3.8 million in 1Q24, and fell short of consensus expectations of $4.6 million. Additionally, the company has revised its revenue projections for the EksoHealth channel downward for 2025 and beyond, citing the potential adverse effects of economic uncertainty. The enterprise segment has also experienced softer revenue due to customer budget cuts, indicating challenges in maintaining sales amid a tightening financial environment.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares